Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Biocon announced the launch of Bosaya™ and Aukelso™ (denosumab-kyqq) in the U.S. and available by prescription nationwide.

Apotex Inc. ("Apotex" or the "Company"), the largest Canadian‑based global pharmaceutical company, today announced that Health Canada has approved DENOZA™ (denosumab injection), a biosimilar ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Prolia should be covered by Medicare Part A, Part B, or Part D, depending on why you need to take the drug and whether you will administer it yourself. Prolia (denosumab) is an injectable monoclonal ...

(RTTNews) - Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Bosaya ...

Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation -- Potential benefit to ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Potential benefit to the estimated 10 million adults with osteoporosis and over 330,000 patients annually with bone ...